This Month in JNM

Rationale for spatial dose mapping: Lassman and Hänscheid summarize the benefits and challenges of current radiopharmaceutical biokinetic models and preview an article in this month's JNM on a novel 3D dose approach for individualized dosimetry.
Page 2

Questioning the ¹⁸F-FDG lump constant: Krohn and colleagues examine the relevance of the ¹⁸F-FDG lump constant in quantitative small animal models of regional brain imaging and pose key questions about a related article in this month's JNM.
Page 5

Nasopharyngeal PET/CT uptake patterns: Chen and colleagues evaluate ¹⁸F-FDG uptake on PET/CT to determine whether characteristic patterns and intensities in areas of Waldeyer's ring can improve the ability to differentiate benign from malignant lesions.
Page 8

Interpreting ¹⁸F-FDG–negative lung nodules: O and colleagues explore the diagnostic challenge of interpreting small pulmonary nodules with little or no perceptible ¹⁸F-FDG uptake and provide insight on strategies for follow-up.
Page 15

Deep breath-hold PET/CT: Nehmeh and colleagues describe their experience with inspiration breath-hold techniques in PET/CT imaging of the thorax and outline the technical aspects required for routine clinical use in reduction of motion artifacts.
Page 22

Assessing presynaptic dopaminergic deficit: Koch and colleagues report on studies in humans demonstrating the use of ^99mTc-NC100697, a new formulation of ^99mTc-TRODAT-1, for estimating presynaptic striatal dopamine transporter binding and discuss potential applications in parkinsonian syndromes.
Page 27

PET and PET/CT in FUO: Meller and colleagues provide an overview of ¹⁸F-FDG PET and PET/CT in the diagnosis of fever of unknown origin, focusing on the ability of PET to diagnose a wider spectrum of disease at earlier stages than conventional approaches.
Page 35

Differential prostate diagnosis: Oka and colleagues explore the feasibility of anti–¹⁸F-FACBC for diagnosing prostate cancer through in vitro and in vivo rat models and assess the potential of this tracer for distinguishing cancer from inflammation and benign prostatic hyperplasia.
Page 46

Anti–¹⁸F-FACBC and prostate cancer: Schuster and colleagues examine the uptake of this synthetic l-leucine analog on PET/CT in patients with newly diagnosed and recurrent prostate carcinoma.
Page 56

Imaging with ⁶⁴Cu-MSH peptide: Wei and colleagues report on the synthesis and initial biologic evaluation of a novel ⁶⁴Cu-labeled candidate for PET imaging of malignant melanoma.
Page 64

Primary and metastatic melanoma imaging: Miao and colleagues assess the potential utility of ^99mTc- and ¹¹¹In-labeled α-melanocyte–stimulating hormone peptides as SPECT/CT imaging probes, using mouse models of primary and metastatic melanoma.
Page 73

P-glycoprotein and PET radioligands: Ishiwata and colleagues investigate the extent to which P-glycoprotein affects 8 radioligands used clinically for PET studies of brain function.
Page 81

Androgen regulation of GRP receptors: de Visser and colleagues evaluate gastrin-releasing peptide receptor expression in 12 established human prostate xenograft models representing progressive disease stages and assess the effect of antiandrogen treatment on each.
Page 88

Lumped constant for small-animal ¹⁸F-FDG PET: Tokugawa and colleagues determine an operational value for the lumped constant to be used in measurements of the local rate of cerebral glucose use in ¹⁸F-FDG PET imaging of normal adult male rats.
Page 94

Dosimetry of ¹⁸F-SPA-RQ: Sprague and colleagues apply 3 methods of image analysis to estimate the radiation safety profile and relative risks of a novel selective radioligand for in vivo PET quantification of tachykinin NK₁ receptors.
Page 100

Iterative segmentation of PET volumes: Jentzen and colleagues report on an iterative thresholding method to estimate PET volumes without a priori anatomic knowledge and describe its application to clinical images.
Page 108

Submillimeter LSO array for PET: Stickel and colleagues provide a description of a small-animal PET configuration designed to meet the increasing demands for high-spatial-resolution imaging in mouse models of disease.
Page 115

Metastatic bone pain palliation: Ogawa and colleagues evaluate the palliative effects of a ¹⁸⁶Re-complex–conjugated bisphosphonate in an animal model of metastatic bone pain.
Page 122

Radiation dosimetry of ¹¹C-PIB: Scheinin and colleagues investigate the biodistribution and radiation dosimetry of the PET amyloid imaging agent ¹¹C-PIB in humans.
Page 128

Kidney dose distribution for PRRT: Konijnenberg and colleagues report on the biodistribution of octreotides used in peptide receptor radionuclide therapy and discuss potential challenges in accurate modeling of renal tissue damage.
Page 134

Normal organ dosimetry with quantitative PET: Kolbert and colleagues describe a method for determining normal organ ¹³¹I dosimetry in patients undergoing radioiodide therapy for thyroid cancer by use of serial scanning with ¹²⁴I PET.
Page 143

¹³¹I vs. ⁹⁰Y lung dosimetry in NHL: Song and colleagues use Monte Carlo–based dosimetry to compare the potential of ⁹⁰Y and ¹³¹I in targeted therapy of lung metastases of various nodule sizes and tumor burdens in non-Hodgkin's lymphoma.
Page 150

Supervised clustering for PET: Turkheimer and colleagues combine reference region modeling with supervised reference tissue extraction to produce a robust and reproducible quantitative assessment technique for ¹¹C-(R)-PK11195 PET studies in the human brain.
Page 158

ON THE COVER

Conventional imaging techniques have serious limitations in the detection, staging, and restaging of prostate carcinoma. PET/CT using anti–1-amino-3-¹⁸F-fluorocyclobutane-1- carboxylic acid (anti–¹⁸F-FACBC), a synthetic l-leucine analog, has demonstrated uptake in prostate carcinoma even when no uptake was found on ¹¹¹In-capromab pendetide imaging. It is feasible that the use of anti–¹⁸F-FACBC might improve the diagnostic imaging of both initial and recurrent prostate carcinoma.

SEE PAGE 61